Sometimes it is identity, with a cheaper compound being substituted entirely
below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans
The strategic differentiation thesis that emerged from the analysis: CT-388 is best positioned as the "Balanced Precision Dual Agonist," differentiated from tirzepatide by equimolar GIP:GLP-1 engagement (1:1 vs 9:1), a distinct peptide scaffold with independent IP, and a five-year extended exclusivity window
To further assess the adverse profile of GLP-1MK-801, we performed a series of complementary studies in mice and rats
Methods A multinational cross-sectional study was conducted across all six World Health Organization regions, involving community-dwelling adults
Retatrutide shows strong promise for weight management and metabolic health when started at a low dose and increased gradually under medical supervision